Methods and uses for treating anhedonia
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12171759-B1
Publication Date
2024-12-24
Expiration Date
Abstract
The present disclosure is directed to, among other things, methods and uses for treating anhedonia in a subject, such as a human, wherein the methods comprise administering a therapeutically effective amount of N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide (Compound A) to the subject in need thereof, and the uses comprise Compound A for use in treating anhedonia in a subject, such as a human. The present disclosure is further directed to various improved methods of therapy and administration of Compound A.
Core Innovation
The invention relates to a method of enhancing the opening of a Kv7 potassium channel in a human suffering from anhedonia by administering Compound A. Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide. The approach is directed to Kv7 potassium channel opening in the human as the functional basis for treating anhedonia.
The document links Compound A to enhancing Kv7 potassium channel opening, including Kv7.2 and Kv7.3, and optionally selecting enhancement over Kv7.1. It proposes a mechanism in which Compound A reverses ventral tegmental area (VTA) hyperactivity through Kv7-mediated M-current enhancement. The activity is described in the context of anhedonia and the associated neurobiological state.
The document describes use in anhedonia subtypes, including sexual anhedonia and social anhedonia, and in neuropsychiatric disorder contexts such as major depressive disorder (MDD), post-traumatic stress disorder (PTSD), schizophrenia, substance-related disorders, and Parkinson's disease. It also reports rodent Progressive Ratio Test findings using lever pressing and break point measures, describing dose-dependent improvements with Compound A, including results noted for “low” responders.
Claims Coverage
The independent claim covers a method that administers Compound A to a human suffering from anhedonia to enhance the opening of a Kv7 potassium channel, yielding a direct link between Compound A and Kv7 channel opening as the claimed inventive concept. One independent claim is provided in the supplied material.
Enhancing Kv7 potassium channel opening for human anhedonia
A method of enhancing the opening of a Kv7 potassium channel in a human, comprising administering an effective amount of Compound A to the human, wherein the human is suffering from anhedonia.
Specific Compound A identity
Compound A is N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide.
Across the provided independent claim language, the claim coverage centers on administering an effective amount of Compound A—defined specifically as N-[4-(6-fluoro-3,4-dihydro-1H-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide—to a human suffering from anhedonia, with the functional requirement of enhancing the opening of a Kv7 potassium channel.
Stated Advantages
Improvement of anhedonia treatment outcomes is described, including dose-dependent increases in Progressive Ratio Test lever pressing and break point for Compound A.
The document describes reversing ventral tegmental area (VTA) hyperactivity through Kv7-mediated M-current enhancement as a proposed therapeutic mechanism.
Documented Applications
Treating anhedonia in a human, including sexual anhedonia and social anhedonia, is explicitly described, with disorder contexts including major depressive disorder (MDD), post-traumatic stress disorder (PTSD), schizophrenia, substance-related disorders, and Parkinson's disease.
Rodent testing application is explicitly described using the Progressive Ratio Test with lever pressing and break point as readouts for Compound A effects.
Interested in licensing this patent?